HomeEVGN • NASDAQ
add
Evogene Ltd
$1.76
Makalipas ang Oras ng Trabaho:(0.57%)+0.0100
$1.77
Sarado: Nob 8, 6:55:21 PM GMT-5 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$1.80
Sakop ng araw
$1.70 - $1.83
Sakop ng taon
$1.70 - $10.40
Market cap
8.90M USD
Average na Volume
527.92K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Hun 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 914.00K | 39.76% |
Gastos sa pagpapatakbo | 6.47M | -20.01% |
Net na kita | -5.42M | 22.84% |
Net profit margin | -592.89 | 44.79% |
Kita sa bawat share | -1.06 | 37.65% |
EBITDA | -5.48M | 24.40% |
Aktuwal na % ng binabayarang buwis | -0.02% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Hun 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 20.91M | -38.28% |
Kabuuang asset | 40.97M | -23.19% |
Kabuuang sagutin | 21.03M | -5.41% |
Kabuuang equity | 19.94M | — |
Natitirang share | 5.10M | — |
Presyo para makapag-book | 3.00 | — |
Return on assets | -34.74% | — |
Return on capital | -64.68% | — |
Cash Flow
Net change in cash
(USD) | Hun 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | -5.42M | 22.84% |
Cash mula sa mga operasyon | -5.46M | -7.15% |
Cash mula sa pag-invest | 3.21M | 140.63% |
Cash mula sa financing | -151.00K | -101.45% |
Net change in cash | -2.43M | 12.14% |
Malayang cash flow | 7.01M | 458.53% |
Tungkol
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
CEO
Itinatag
2002
Website
Mga Empleyado
142